Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan
Eagle Pharmaceuticals (OTCMKTS: EGRX) announced that its Board amended and extended the company’s limited duration stockholder rights plan by one year to October 30, 2026, effective immediately.
The amendment was made in response to ongoing significant trading-price dislocation and increases the potential dilution an acquirer would face if the plan is triggered. Rights become exercisable if a person or group acquires ≥10% beneficial ownership (or ≥15% for passive institutional investors). Grandfathered holders above the thresholds remain at current levels but may not increase ownership without triggering the plan.
Each exercisable Right permits purchase for $20.00 of shares with a market value equal to twice that price; the Rights Plan will expire automatically on October 30, 2026 unless redeemed or exchanged earlier.
Eagle Pharmaceuticals (OTCMKTS: EGRX) ha annunciato che il suo Consiglio ha modificato ed esteso il piano di diritti degli azionisti a durata limitata della società di un anno, portandolo a 30 ottobre 2026, con effetto immediato.
La modifica è stata apportata in risposta a una persistente significativa dislocazione del prezzo di negoziazione e aumenta la potenziale diluizione che un acquirente potrebbe affrontare se il piano venisse attivato. I diritti diventano esercitabili se una persona o un gruppo acquisisce ≥10% di proprietà vantaggiosa (o ≥15% per gli investitori istituzionali passivi). I titolari già presenti oltre le soglie rimangono ai livelli attuali ma non possono aumentare la proprietà senza far scattare il piano.
Ogni Diritto Esercitabile consente l'acquisto di azioni per $20,00 di valore di mercato pari al doppio di tale prezzo; il Piano dei Diritti scadrà automaticamente il 30 ottobre 2026, a meno che non venga rimborsato o scambiato prima.
Eagle Pharmaceuticals (OTCMKTS: EGRX) anunció que su Junta modificó y prorrogó el plan de derechos de los accionistas de duración limitada de la compañía por un año, llevándolo al 30 de octubre de 2026, con efecto inmediato.
La modificación se realizó en respuesta a una persistente y significativa dislocación en el precio de negociación y aumenta la dilución potencial a la que se enfrentaría un adquirente si se activa el plan. Los derechos se vuelven exercitables si una persona o grupo adquiere ≥10% de propiedad beneficiosa (o ≥15% para inversores institucionales pasivos). Los titulares grandfathered por encima de los umbrales permanecen en los niveles actuales pero no pueden aumentar la propiedad sin activar el plan.
Cada derecho ejercitable permite comprar por $20,00 acciones con un valor de mercado igual al doble de ese precio; el plan de derechos expirará automáticamente el 30 de octubre de 2026 a menos que se canjee o cancele antes.
Eagle Pharmaceuticals (OTCMKTS: EGRX)는 이사의 결의로 회사의 제한 기간 주주 권리 계획을 1년 연장하여 2026년 10월 30일로 즉시 발효되었다고 발표했다.
개정은 지속적인 거래가격의 상당한 불일치에 대응하기 위해 이루어졌으며, 계획이 발동될 경우 매수자가 직면하게 될 잠재적 희석을 증가시킨다. 권리는 누군가가 ≥10%의 실질 소유권을 취득하거나(또는 비활발한 기관 투자자일 경우 ≥15%)에 도달하면 실행 가능해진다. 상한치를 넘은 기존 보유자는 현재 수준으로 남지만 계획이 발동되지 않도록 소유를 늘릴 수 없다.
각 실행 가능한 권리는 주당 가치가 $20.00의 주식을 매수할 수 있게 하며, 그 주식의 시가가 그 가격의 두 배에 해당한다; 권리 계획은 2026년 10월 30일에 자동으로 만료되며, 이전에 상환되거나 교환되지 않는 한.
Eagle Pharmaceuticals (OTCMKTS: EGRX) a annoncé que son Conseil a modifié et prorogé le plan des droits des actionnaires à durée limitée de l'entreprise d'un an, le portant au 30 octobre 2026, avec effet immédiat.
L'amendement a été apporté en réponse à une dissociation continue significative du prix de négociation et augmente la dilution potentielle à laquelle serait confronté un acquéreur si le plan est déclenché. Les droits deviennent exerçables si une personne ou un groupe acquiert ≥10% de propriété bénéficiaire (ou ≥15% pour les investisseurs institutionnels passifs). Les titulaires déjà établis au-delà des seuils restent au niveau actuel mais ne peuvent pas augmenter la propriété sans déclencher le plan.
Chaque droit exécutable permet d'acheter pour $20.00 d'actions dont la valeur marchande est le double de ce prix; le plan de droits expirera automatiquement le 30 octobre 2026 à moins d'être racheté ou échangé plus tôt.
Eagle Pharmaceuticals (OTCMKTS: EGRX) gab bekannt, dass der Vorstand den unternehmensweiten Aktienbesitzer-Rechteplan mit einer Verlängerung um ein Jahr auf 30. Oktober 2026 geändert und in Kraft gesetzt hat.
Die Änderung wurde vorgenommen, um auf eine anhaltende signifikante Kursabweichung zu reagieren und die potenzielle Verwässerung zu erhöhen, der ein Erwerber gegenüberstehen würde, falls der Plan ausgelöst wird. Rechte werden ausübbar, wenn eine Person oder Gruppe ≥10% Beneficial Ownership erwirbt (bzw. ≥15% für passive institutionelle Investoren). Berechtigte Inhaber über den Schwellen bleiben auf dem aktuellen Niveau, dürfen jedoch kein Eigentum erhöhen, ohne den Plan auszulösen.
Jedes ausübungsbereite Recht ermöglicht den Kauf von Aktien im Wert von $20.00, wobei der Marktwert dem Doppelten dieses Preises entspricht; der Rights Plan läuft automatisch am 30. Oktober 2026 ab, es sei denn, er wird vorher eingelöst oder getauscht.
Eagle Pharmaceuticals (OTCMKTS: EGRX) أعلنت أن مجلس إدارتها عدل ووسع خطة حقوق المساهمين ذات المدة المحدودة للشركة بمقدار سنة واحدة لتصبح 30 أكتوبر 2026، سارية المفعول فوراً.
تم إدراج التعديل استجابةً لاستمرار وجود اختلال سعر التداول بشكل كبير ويزيد من التخفيف المحتمل الذي قد يواجهه المشتري إذا تم تفعيل الخطة. تصبح الحقوق قابلة للممارسة إذا حصل شخص أو مجموعة على ملكية مفيدة بنسبة ≥10% (أو ≥15% للمستثمرين المؤسسيين غير النشطين). يبقى حاملو الحقوق القدامى فوق العتبات عند المستويات الحالية لكن لا يجوز لهم زيادة الملكية دون تفعيل الخطة.
كل حق قابل للممارسة يسمح بشراء أسهم بقيمة $20.00 من الأسهم ذات قيمة سوقية تساوي ضعف ذلك السعر؛ ستنتهي خطة الحقوق تلقائياً في 30 أكتوبر 2026 ما لم يتم استردادها أو تبادلها في وقت أقرب.
- One-year extension of Rights Plan to October 30, 2026
- Trigger thresholds set at 10% (general) and 15% (passive institutions)
- Exercise price $20.00 with share value equal to twice exercise price
- Extension increases potential dilution for unsolicited acquirers if triggered
- May deter activist investors or limit open-market accumulation near thresholds
- Grandfathering prevents increased ownership above thresholds, restricting some investors
Insights
Board extended a limited-duration rights plan to Oct 30, 2026, aiming to deter opportunistic accumulation amid share‑price dislocation.
The amendment extends the Rights Plan by one year to
This is a defensive corporate‑governance move that increases potential dilution for an acquiring party and preserves board flexibility to evaluate offers; the Board states the extension is a response to trading dislocation and not to a specific takeover threat. Key dependencies and risks include the market price relative to the
WOODCLIFF LAKE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has adopted an amendment (the “Amendment”) to its existing limited duration stockholder rights plan (as amended, the “Rights Plan”) to extend the duration of the Rights Plan by one year to October 30, 2026, effective immediately.
The amendment to the Rights Plan was adopted in response to the ongoing significant dislocation in the trading price of the Company’s common stock. The amendment will have the effect of increasing the potential dilution an Acquiring Person would potentially face if the Rights Plan were triggered. Accordingly, the Rights Plan, as amended, is intended to enable all of the Company’s stockholders to have the opportunity to realize the long-term value of their investment and reduce the likelihood that any person or group gains control of the Company through open market accumulation or other means without appropriately compensating all stockholders or without providing the Board sufficient time to make informed judgments and take actions that are in the best interests of the Company and its stockholders.
The Board did not adopt the extension to the Rights Plan in response to a specific takeover threat. In addition, the Rights Plan does not prevent the Board from engaging with parties or accepting an acquisition proposal, if the Board believes that it is in the best interests of the Company and all of its stockholders.
The Rights Plan, as amended, will automatically expire on October 30, 2026, unless the rights are earlier redeemed or exchanged by the Company. The Rights will be exercisable only if a person or group (an “Acquiring Person”) acquires or launches a tender or exchange offer to acquire beneficial ownership (which includes certain synthetic equity interests) of
Eagle’s stockholders do not need to take any further action with respect to the rights or the Rights Plan at this time.
About Eagle Pharmaceuticals, Inc.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. Additional information is available on Eagle’s website at www.eagleus.com.
Forward-Looking Statements
This press release contains “forward-looking statements” regarding future events or our future financial performance. Forward-looking statements are statements that are not historical facts. Words and phrases such as “anticipated,” “forward,” “will,” “would,” “could,” “may,” “intend,” “remain,” “regain,” “maintain,” “potential,” “prepare,” “expected,” “believe,” “plan,” “seek,” “continue,” “goal,” “estimate,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements with respect to: the impacts of the adoption of the Rights Plan, including the ability of the Rights Plan to protect stockholders’ ability to realize the long-term value of their investment and to effectively provide the Board sufficient time to make informed judgments and take actions that are in the best interests of the Company and its stockholders, and expectations regarding the Company’s process to review potential financing and other alternatives, including the types of arrangements or transactions, if any, that the Company may determine to pursue, the scope and timing of such review process, the potential value of any such arrangements or transactions and the outcome of such review process. All such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the Company’s control, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks and uncertainties include, but are not limited to: global economic and political conditions; the Company’s reliance on third parties to manufacture commercial supplies of its products and clinical supplies of its product candidates; delay in or failure to obtain regulatory approval of the Company’s or its partners’ product candidates and successful compliance with Federal Drug Administration, European Medicines Agency and other governmental regulations applicable to product approvals; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; whether the Company can successfully market and commercialize its products; the success of the Company's relationships with its partners; changes in applicable laws and regulations; the limitations on trading of the Company’s common stock related to the Company’s trading on the OTC Expert Market; the impact on the price of the Company’s common stock and the Company’s reputation; the Company’s ability to remediate material weaknesses in its internal control over financial reporting; the Company’s ability to recruit, hire and retain key personnel; the ability of the Company to realize the anticipated benefits of its plan designed to improve operational efficiencies and realign its sales and marketing expenditures and the impacts thereof; the Company’s reliance on third parties to manufacture commercial supplies of its products and clinical supplies of its product candidates; the impacts of geopolitical factors such as the conflicts between Russia and Ukraine and Hamas, Iran and Israel; delay in or failure to obtain regulatory approval of the Company’s or its partners’ product candidates and successful compliance with Federal Drug Administration, European Medicines Agency and other governmental regulations applicable to product approvals; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; whether the Company can successfully market and commercialize its products; the success of the Company's relationships with its partners; the outcome of litigation and other legal proceedings and the risk of additional litigation and legal proceedings; the strength and enforceability of the Company’s intellectual property rights or the rights of third parties; competition from other pharmaceutical and biotechnology companies and competition from generic entrants into the market; unexpected safety or efficacy data observed during clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the risks inherent in drug development and in conducting clinical trials; risks inherent in estimates or judgments relating to the Company’s critical accounting policies, or any of the Company’s estimates or projections, which may prove to be inaccurate; and unanticipated factors in addition to the foregoing that may impact the Company’s financial and business projections and may cause the Company’s actual results and outcomes to materially differ from its estimates and projections. Readers are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Relations Contact
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
What did Eagle Pharmaceuticals (EGRX) announce on October 30, 2025?
How does the EGRX Rights Plan trigger and what are the ownership thresholds?
What is the exercise price and economic effect of each Right under EGRX's plan?
When will the EGRX Rights Plan expire if not redeemed?
Are existing large shareholders affected by the EGRX extension?
Does the EGRX Rights Plan prevent the Board from accepting acquisition offers?
